{"id":"NCT00130208","sponsor":"Keryx Biopharmaceuticals","briefTitle":"Effect of Sulodexide in Early Diabetic Nephropathy","officialTitle":"The Collaborative Study Group Trial: The Effect of Sulodexide in Patients With Type 2 Diabetes and Microalbuminuria","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-08","primaryCompletion":"2008-01","completion":"2008-02","firstPosted":"2005-08-15","resultsPosted":"2018-03-23","lastUpdate":"2018-03-23"},"enrollment":1056,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Diabetic Nephropathy"],"interventions":[{"type":"DRUG","name":"Sulodexide","otherNames":["KRX-101"]},{"type":"DRUG","name":"Placebo","otherNames":["Placebo oral gelcap"]}],"arms":[{"label":"Sulodexide","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study is to determine whether treatment with sulodexide is effective in reducing the level of urine albumin excretion in patients with early diabetic kidney disease expressed as microalbuminuria.","primaryOutcome":{"measure":"Number of Subjects With Conversion From Microalbuminuria to Normoalbuminuria","timeFrame":"26 Weeks","effectByArm":[{"arm":"Sulodexide","deltaMin":39,"sd":null},{"arm":"Placebo","deltaMin":30,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":23},"locations":{"siteCount":3,"countries":["United States","Australia","Netherlands"]},"refs":{"pmids":["21872376"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":21,"n":523},"commonTop":["Edema Peripheral","Upper Respiratory Tract Infection","Diarrhea","Nasopharyngitis","Urinary Tract Infection"]}}